CND Life Sciences’ Syn-One® Biomarker Services Advance Parkinson’s Research in Phase 2 Clinical Trial
PHOENIX, AZ – November 11, 2025 — CND Life Sciences, a pioneering neurodiagnostic company, announced that its Syn-One® Biomarker...
AHA 2025
Advertisement
Cytokinetics Presents New MAPLE-HCM Data at AHA 2025, Strengthening Pipeline in Rare Cardiomyopathy Therapy
San Francisco, November 10, 2025 — Cytokinetics, Inc., a biopharmaceutical company focused on developing muscle biology–driven therapies, announced the...
Bristol Myers Squibb Unveils New Long-Term and Real-World Data for Camzyos at AHA 2025
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
Advertisement
